Linagliptin in Heart Failure Management

Introduction to Linagliptin's Safety Profile

• The American Diabetes Association recommends linagliptin as an acceptable DPP-4 inhibitor choice for patients with heart failure when glycemic control is needed, although SGLT2 inhibitors are preferred due to their proven mortality and morbidity benefits 1
• Linagliptin does not increase the risk of heart failure hospitalization, as demonstrated by the CARMELINA trial, which included 6,979 patients with type 2 diabetes at high cardiovascular and renal risk 1

Evidence for Linagliptin's Efficacy and Safety

• The CARMELINA trial showed that linagliptin has a neutral effect on the composite of cardiovascular death/heart failure hospitalization (HR 0.94, 95% CI 0.82-1.08) 1
• Linagliptin demonstrated no increase in heart failure hospitalization risk (HR 0.90, 95% CI 0.74-1.08) compared to placebo in the CARMELINA trial 1
• The American Heart Association and the Heart Failure Society of America conclude that the risk-benefit balance for most DPP-4 inhibitors does not justify their use in patients with established heart failure or those at high risk for heart failure, although linagliptin data were still pending at the time of the statement 3, 2

Clinical Positioning of Linagliptin

• SGLT2 inhibitors remain the preferred first-line glucose-lowering agents for patients with heart failure, with a 35% reduction in heart failure hospitalization with empagliflozin and a 39% reduction with canagliflozin 1
• Linagliptin has a role when SGLT2 inhibitors are contraindicated or not tolerated, or when additional glycemic control is needed beyond SGLT2 inhibitors and other guideline-directed therapies 1
• The American College of Cardiology and the American Heart Association recommend considering linagliptin for patients with severe renal impairment, where dosing simplicity is advantageous (no adjustment needed) 3, 2

Practical Considerations for Linagliptin Use

• The FDA label warns of an association between DPP-4 inhibitor treatment and heart failure, and recommends considering the risks and benefits prior to initiating treatment in patients at risk for heart failure 1
• The American Diabetes Association recommends monitoring for signs and symptoms of worsening heart failure and assessing glycemic control (HbA1c) within 3 months of initiating linagliptin therapy 1
• Linagliptin provides no cardiovascular benefit and is cardiovascularly neutral, not protective 1, 2